POZNAŃ 2018
GENERAL ASSEMBLY, SCIENTIFIC CONFERENCES AND RELATED EVENTS

Poznań, Poland
June 19th - 22nd 2018
IBB Andersia Hotel
Welcome to OECI Oncology Days 2018

The annual convention of the Directors of the European Cancer Centres and Institutes is hosted in Poland for the first time. This year is a major milestone event for the OECI as it is the celebration of the OECI’s 40th Anniversary since the very first meeting of the Directors of some of the main European Cancer Centres back in 1979.

Our Anniversary is saddened by the premature and unexpected passing of Professor Thomas Tursz, former Director of the Institut Gustave Roussy. Thomas covered the position of OECI President from 2002 to 2005, launching the Accreditation and Designation Programme as a main instrument to certify the quality of European Cancer Centres. Thomas was a combination of a great scientist and a good clinician, as well as an outstanding medical director. Leader of French cancer care and loved person that always privileged the group over the individual, he inspired with his work a whole generation of oncologists. We will miss him dearly and we want to dedicate the 40th Meeting of the OECI Directors to this generous and outstanding member of our community.

We will remember him with his smile and jokes that always cheered up our social events.

2018 is the transitional year of my presidential mandate and Professor Thierry Philip will be taking over the Chair of OECI, with the intention of carrying forward the running activities and leading our Organisation towards new challenges and achievements, promoting multidisciplinarity, integration and quality in the organisation of our Cancer Centres.

Thanks to the dedicated and assiduous support of the OECI Offices and the Board Members, during the four years of my Presidency, OECI has developed a more solid and federated organisational structure. This has given us the possibility to better reach our goals through inclusivity, and to involve more members to interact and establish partnerships with other like-minded Organisations, which share a common vision. An open and transparent interaction amongst all the main cancer actors is a mandatory pre-condition, justifying our efforts and confirming that we are committed to serve our patients and the progress of science.

A Cancer Centre is the central place where multi-disciplinarity is implemented and the OECI Cancer Centres represent the advanced front of innovation, the place where research and applications are studied and approaches of care are compared, with a view to offering patients the best options for therapy and well-being.

The annual meeting represents an ideal setting for holding a productive exchange of views and I invite you to make the most of this meeting and the relaxed and confidential atmosphere of the social events we have organised for our participants to discuss common strategies.

Again this year, we decided to leave space in our programme for all our Working Groups to also meet, in addition to the Directors of our Centres/Institutes, and other stakeholders working in different sectors, giving them the opportunity to draw upon results already obtained or to pursue further collaboration for the achievements of their goals.

The increase in survivorship has also reinforced the issue of patient rights to access a dignified and active life in society, during and post illness, on top of the best options for cure and therapeutic solutions. After my Presidency, I will continue to chair the WG on Collaboration for Good Practices with Patients and I will have more time to dedicate to the actions we are currently developing in order to strengthen our relationship with patients, demonstrating how they are at the centre of all our efforts.

It has been a great honour to serve as your President for the last four years. The OECI is a unique and essential Organisation for the development and recognition of all the hard work done by all the professionals in our Cancer Centres.

I wish you a pleasant stay in Poznań and very constructive interactions during these OECI 2018 Oncology Days!

Dominique de Valeriola
OECI President
OECI2018 ONCOLOGY DAYS
Greater Poland Cancer Centre
Director’s welcome

THE 40TH OECI ANNIVERSARY: WELCOME TO POZNÀN

The year 2018 marks the 40th Anniversary of the founding of the Organisation of European Cancer Institutes (OECI).

The OECI 40th Anniversary is held in Poznań, Poland, from June 20th to June 22nd in collaboration with the Greater Poland Cancer Centre (GPCC). In honour of the 40th OECI Anniversary, the “2018 OECI Oncology Days” covers a range of topical issues in oncology. In particular the 2018 OECI Scientific Conference “Emerging technologies in therapies against cancer: what best to select for cancer centres?” focuses on the most relevant technologies for cancer patients and cancer treatment centres.

The proposed Sessions include many of the hottest topics in oncology, including “Limiting invasiveness of radiotherapy”, “Debating the future of Hadrontherapy”, “Minimally-invasive technologies”, and “Analysis of economic issues for emerging technologies in health care”.

Poznań is a charming university city and we are certain that participants will enjoy the opportunity to explore the City, especially the historic old town. Participants are encouraged to take a tour of our facilities at the GPCC, which is, coincidentally, celebrating this year its 65th Anniversary.

We believe that the university atmosphere of Poznań, together with the long medical tradition in our City, will provide an excellent setting in which to exchange knowledge and to discuss important issues in oncology. The Oncology Days will also provide an excellent opportunity to meet old friends, as well as to make new friends and new scientific contacts.

The GPCC is truly honoured to be hosting both the 40th OECI Anniversary and the 2018 Oncology Days.

On behalf of the OECI and the GPCC, we look forward to seeing you in Poznań.

Prof. Julian Malicki
Director of the Greater Poland Cancer Centre in Poznań

ONE MORE REASON TO JOIN THE OECI IS CERTIFYING YOUR QUALITY IN ONCOLOGY!
The OECI Board

**President**
Dominique de Valeriola
Brussels, Belgium

**Former President**
Wim H. van Harten
Amsterdam, The Netherlands

**Treasurer**
José Maria Laranja Pontes
Porto, Portugal

**Elected Member**
Carlos Caldas
Cambridge, United Kingdom

**Elected Member**
József Lövey
Budapest, Hungary

**President Elect**
Thierry Philip
Paris, France

**Executive Secretary**
Marco A. Pierotti
Milan, Italy

**Elected Member**
Gunnar Sæter
Oslo, Norway

**Elected Member**
Christof von Kalle
Heidelberg, Germany

**OECI Director**
Claudio Lombardo
Brussels, Belgium - Genoa, Italy

**OECI Central Office**
Guy Storme
Brussels, Belgium

Working Groups and Activities

**Accreditation and Designation**
Simon Oberst
Cambridge, United Kingdom

**Biobanks and Molecular Pathobiology**
Giorgio Stanta
Trieste, Italy

**Cancer Economics and Benchmarking**
Wim H. van Harten
Amsterdam, The Netherlands

**Cancer Outcomes Research**
Milena Sant
Milan, Italy

**Supportive and Palliative Care**
Tiina Hannele Saarto
Helsinki, Finland

**Collaboration for Good Practices with Patients**
Dominique de Valeriola
Brussels, Belgium

**START-OECI**
Lisa Licitra
Milan, Italy

**Communication and Dissemination**
Gordon McVie
Milan, Italy

**Claudio Lombardo**
Brussels, Belgium - Genoa, Italy

OECI Members A&D certified
Comprehensive Cancer Centre
OECI Members A&D certified
Clinical Cancer Centre
OECI Members in the A&D process
Other OECI Members
The OECI membership

Austria
- Comprehensive Cancer Center Graz, Graz
- Comprehensive Cancer Center Vienna, Wien
- Zentrum für Tumorerkrankungen Linz Onkologisches Leitspital für Oberösterreich, Linz

Belgium
- Institut Jules Bordet (IJB), Brussels
- Kankercentrum Brussel, Brussels
- AZ Groeninge, Kortrijk
- Institut Roi Albert II Cliniques universitaires Saint-Luc, Brussels

Croatia
- Klinika za tumore Klinicki bolnicki centar Sestre milosrdnice, Zagreb

Czech Republic
- Masarykův onkologický ústav, Brno
- Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno

Denmark
- Veje Sygehus Patienternes Kraftsygehus, Veje
- Kraftens Bekæmpelse Center for Kraftrørsning, Copenhagen

Estonia
- Siltasutus Tartu Ülikooli Kliinikum, Tartu
- North Estonia Medical Centre, Tallin

Finland
- HYKS Söpäkeskus Helsinki University, Helsinki
- TYKS Söpäkeskus, Turku
- Tampereen Yliopistollinen sairaala, Tampere

France
- Gustave Roussy, Villejuif
- Centre Léon Bérard, Lyon
- Institut Curie, Paris
- Institut Paoli-Calmettes, Marseille
- Centre de Lutte Contre le Cancer Paul Strauss, Strasbourg
- Centre Jean Perrin, Clermont-Ferrand
- Centre Henri Beccquerel, Rouen

Germany
- Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
- Universitäts Krebszentrum Dresden, Dresden
- Charité Comprehensive Cancer Centre, Berlin
- Onkologisches Zentrum der Technischen Universität München, München
- 9 Onkologisches Zentrum der Ludwig-Maximilians-Universität München, München
- German Cancer Research Center (DKFZ), Heidelberg
- IRCCS Centro di Riferimento Oncologico dell' Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS CROB), Rionero in Vulture, Italy
- Azienda Unità Sanitàire Locale di Reggio Emilia - IRCCS, Reggio Emilia
- Ospedale R. Raffaele (OSR), Milano
- European School of Oncology (ESO), Milano

Ireland
- Trinity St. James's Cancer Institute, Dublin

Italy
- Centro di Riferimento Oncologico, Istituto Nazionale Tumor, Aviano
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST - Istituto Nazionale per la Ricerca sul Cancro, Genova
- Istituto Europeo di Oncologia, Milano
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano
- Istituto Nazionale Tumori Regina Elena, Roma
- Istituto Oncologico Veneto IRCCS-IOV, Padova
- IRCCS Istituto Clinico Humanitas, Milano
- Istituto Tumori Giovanni Paolo II, di Ricerca e Curazione, Milano
- Istituto Nazionale Tumori Regina Elena, Roma
- Istituto Oncologico Veneto IRCCS-IOV, Padova
- Centro di Riferimento Oncologico dell' Istituto di Ricovero e Cura a Carattere Scientifico, Bari
- Istituto Nazionale Tumori IRCCS - Istituto di Ricerche Studio e la Cura dei Tumori [IRST]-IRCCS, Trieste
- Centro di Riferimento Oncologico, Genova

Lithuania
- National Cancer Institute, Vilnius

Netherlands
- Amsterdam UMC, Amsterdam
- Erasmus MC Cancer Institute, Rotterdam
- KLIN Integraal Kankercentrum Nederland, Utrecht
- Radboudumc Centrum voor Oncologie, Nijmegen
- Rijnstate, Arnhem
- University Medical Center Groningen (UMCG), Groningen

Portugal
- Instituto Português de Oncologia do Porto Francisco Gentil E.P.E. (IPO-Porto), Porto
- Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPO-Lisboa), Lisbon
- Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E. (IPO-Coimbra), Coimbra

Poland
- Wielkopolskie Centrum Onkologii, Poznań

Russia
- Tatarstan Cancer Center “TCC”, Kazan
- N.N. Blokhin Russian Cancer Research Centre, Moscow
- National Medical Research Radiological Centre (NMIRRC), Moscow

Serbia
- Oncology Institute of Vojvodina, Sremska Kamenica

Slovakia
- Ústav experimentálnej onkológie SAV, Bratislava

Spain
- Onkološké Ústav Ljubljana, Ljubljana

Sweden
- Karolinska Institute and University Hospital, Stockholm
- Skåne University Hospital South Sweden Cancer Centre, Lund
- Uppsala University Hospital, Uppsala

The Netherlands
- Netherlands Cancer Institute, Amsterdam
- Maastricht University Medical Centre, Maastricht
- Erasmus MC Cancer Institute, Rotterdam
- KNIL Integraal Kankercentrum Nederland, Utrecht
- Radboudumc Centrum voor Oncologie, Nijmegen
- Rijnstate, Arnhem
- University Medical Center Groningen (UMCG), Groningen

Turkey
- Anadolu Saglik Merkezi (Anadolu Medical Center), Kocaeli
- Dokuz Eylül Üniversitesi Onkoloji Enstitüsü, Izmir

Ukraine
- RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology (IEPOR), Kyiv

United Kingdom
- The Christie NHS Foundation Trust, Manchester
- Cambridge Cancer Centre, Cambridge
- King's Health Partners Integrated Cancer Centre, London
- Imperial College Healthcare NHS Trust, London
Director’s foreword
Our Institution uses the most advanced therapeutic methods in the fight against neoplastic diseases with the hope of restoring patients to health while fully respecting their dignity.

Description of the Centre and history
The Greater Poland Cancer Centre was established in 1953 and is one of the largest oncology centres in Poland and in Europe. The centre provides medical service in the field of oncological surgery, head and neck cancer surgery, radiotherapy, chemotherapy, gynaecological oncology, anaesthesiology, brachytherapy, and diagnostics. Over 20,000 patients are admitted to the hospital each year, and more than 6,000 surgical procedures and 6,500 radiotherapy treatments are performed annually.

Main research activities
The centre’s primary research activity involves clinical studies, such as the high profile clinical trials Hypoprost and Cyberprost for prostate cancer and the HIOB trial for intraoperative breast radiotherapy. EORTC lines of investigation include the following: the origin of ovarian cancer; HPV infection in head and neck cancer; contributions to the cancer genome atlas; the physics-related and biological processes during radiotherapy; the effect of cytostatic agents and ionizing radiation on cancer cells; and molecular imaging in radiation therapy planning.

Core facilities
Following the European model, interdisciplinary teams provide a comprehensive care according to cancer localisation in the body. These multidisciplinary teams work closely together to treat patients with cancers in a given location, such as the breast, the upper digestive tract, or the head and neck area. These teams are mainly led by physicians from various specialisations (e.g., surgery, radiation oncology, medical oncology) in addition to psychologists, physical therapists, nurses, and other supporting personnel (e.g., social workers or dieticians).

Education
WCO has established a Teaching and Conference Centre, which aims to serve the needs health care personnel, patients, and medical students from the Poznan University of Medical Sciences as well as other universities have. Additionally, a variety of training courses, scientific conferences, and symposia are organised each year for both Polish and foreign physicians and other health care professionals.

The Greater Poland Cancer Centre is also home to the editorial offices of four international scientific journals:
1) Reports of Practical Oncology and Radiotherapy,
2) Letters in Oncology Science,
3) Contemporary Oncology
4) Journal of Contemporary Brachytherapy.
### General Timetable

<table>
<thead>
<tr>
<th>Date</th>
<th>Morning</th>
<th>Afternoon</th>
<th>Evening</th>
</tr>
</thead>
<tbody>
<tr>
<td>19 June</td>
<td>Pathology Day</td>
<td>Supportive &amp; Palliative Care WG Session</td>
<td>Board and Pathology Dinner</td>
</tr>
<tr>
<td></td>
<td>Development of Clinical Cancer Research</td>
<td>A survey of palliative care services in OECI certified Centres</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9.45 – 12.30</td>
<td>15.00 – 18.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Girona Hall</td>
<td>Room Ibiza</td>
<td></td>
</tr>
<tr>
<td>20 June</td>
<td>Lunch</td>
<td>JARC WP5 consensus meeting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lunch</td>
<td>15.00 – 18.00</td>
<td></td>
</tr>
<tr>
<td>21 June</td>
<td>Lunch</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>22 June</td>
<td>Lunch</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>

### Scientific Conference

**Emerging technologies in therapies against cancer: what best to select for cancer Centres?**

- **9.00 – 13.20**
- **14.00 – 16.00**
- **16.00 – 17.30**

**Collaboration for Good Practices with Patients WG Session**

**Expanding Patient Involvement in Quality Improvement**

- **16.00 – 17.30**

**Scientific Conference Dinner**

**Gala Dinner Bazar Poznanski**

### Accreditation & Designation Board Meeting

**8.00 – 13.00**

**Accreditation & Designation WG Session**

**OECI re-accreditation proposals: how to focus on quality improvements whilst not overburdening Centres**

- **15.00 – 16.00**

### General Assembly

**8.00 – 13.00**

**Restricted to OECI Members Delegates**

**Girona Hall**

### Supportive & Palliative Care WG Session

**Feasibility of an OECI collaborative study on cancer outcomes**

- **15.00 – 18.00**

**Room Ibiza**

**Walencja Hall**

### Pathology Day

**Development of Clinical Cancer Research**

- **15.00 – 18.00**

**Girona Hall**

### Board & Extended Board meetings

- **15.00 – 19.00**

**Restricted to Board & Extended Board Members**

**Room Ibiza**

### Collaboration for Good Practices with Patients WG Session

**Expanding Patient Involvement in Quality Improvement**

- **16.00 – 17.30**

**Walencja Hall**

### Accreditation & Designation WG Session

**OECI re-accreditation proposals: how to focus on quality improvements whilst not overburdening Centres**

- **16.00 – 17.30**

**Walencja Hall**

### Scientific Conference

**Emerging technologies in therapies against cancer: what best to select for cancer Centres?**

- **9.00 – 13.20**

**Girona Hall**

### Day 3 (20 June)

**Scientific Conference Dinner**

- **9.45 – 12.30**

**Girona Hall**

### Day 4 (21 June)

**Gala Dinner Bazar Poznanski**

- **9.00 – 13.20**

**Girona Hall**

### Day 5 (22 June)

**Scientific Conference Dinner**

- **9.00 – 13.20**

**Girona Hall**

### Day 6 (23 June)

**Gala Dinner Bazar Poznanski**

- **9.00 – 13.20**

**Girona Hall**
There has been a recent development in oncology that has led to the application of clinical research methods directly to patients under treatment. This is a result of the fact that our knowledge of cancer biology and the sophisticated analytical methods used, go beyond the usual randomisation process performed in clinical trials. Indeed, recent literature has shown that individual tumours, within a particular type of cancer, often exceed the most up-to-date molecular classification, and the limits between distinct cancer types. This has recently led to new approaches such as basket, umbrella and platform studies, and to the suggestion of N1 trials, as already discussed in the meeting held in Brno last year.

A necessary prerequisite to this type of clinical studies is the possibility to exchange reproducible analysis results among institutions. The update of the OECI accreditation standards is strongly related to the need to guarantee reproducible investigations. For the above reasons it is mandatory to continue the already started process of standardisation and guideline definition on analytical methods to be adopted, taking also into consideration new molecular morphology approaches.

09.45-10.00 Opening of the Pathology Day 2018
Chairs: Andrzej Marszalek and Giorgio Stanta

10.00-11.00 PRECISION ONCOLOGY: INTRODUCTION
10.00-10.30 Introduction to clinical research in today's oncology
Giorgio Stanta
10.30-11.00 New types of clinical studies (N-1 trials, basket, umbrella and platform studies)
Dalibor Valik

11.00-12.30 PREANALYTICAL CONDITIONS IN CLINICAL MATERIAL
11.00-11.30 Standardisation of pre-analytical conditions of biological material: SPIDIA4P project
Uwe Oelmueller
11.30-12.00 RNA from Clinical Tissues
Serena Bonin

12.00-13.30 Lunch break

13.30-14.30 MOLECULAR MORPHOLOGY
13.30-14.00 New types of methods in molecular morphology: new developments in situ hybridisation
Nicola Crosetto
14.00-14.30 In situ profiling of tumours
Carina Strell

14.30-15.30 RARE CANCER APPROACH
14.30-15.00 Rare cancers as an example of analytical methods to be adopted for a better approach to cancer diagnosis and care (EURACAN)
Mateusz Spalek
15.00-15.30 Common cancers as rare clinical entities: an increasingly frequent recognition
Manfred Dietel

15.30-16.00 Coffee Break

16.00-16.15 Sharing Patient-Derived tumor Xenografts for collaborative research and multicentre preclinical trials: the EuroPDX Research Infrastructure project EDiReX
Enzo Medico

16.15-18.00 ROUND TABLE ON PRECISION PATHOLOGY IN ONCOLOGY
Chairs: Manfred Dietel and Giorgio Stanta
Participants: Denis Larsimont, Rares Buiga, Peeter Padrik, Ildiko Horvath, Gunnar Sæter, Dmitry Borisov, Iryna Shepelenko, Beata Jagielska (participants to be confirmed)
Supportive and Palliative Care Working Group Session

A survey of palliative care services in OECI certified Centres

The meeting aims to present, discuss and launch a survey on how supportive and palliative care is organised in all the OECI certified Centres, standardising the approaches at European level.

The survey will be the basis on which to realise a reference document for cancer patients and European cancer Centres/Institutes on a common view of supportive and palliative care.

15.00-15.20 OECI Supportive and Palliative Care working group: objectives and future working plan
Tiina Hannele Saarto

15.20-15.40 Mission of the Palliative Care Services in the OECI Members. A survey of the present status of Palliative Care in OECI certified Cancer Centres
Tiina Hannele Saarto

15.40-16.20 Discussion

16.20-17.20 European network of Oncology and Palliative Care Services: a shared vision of modern palliative care of cancer patients
Matt Aapro
Stein Kaasa
Danila Valenti

17.05-17.20 Discussion

17.20-17.40 A common research program of the OECI Institutes and research collaboration between European Oncology and Palliative Care Organisations
Stein Kaasa

17.40-18.00 Discussion and conclusion

JARC consensus meeting

EU Joint Action on Rare Cancers

15.00-18.00 Presentation of Draft Quality Standards for Rare Cancer Networks and Feedback
1. Rationale for the Quality Standards and General Framework
Simon Oberst
2. Presentation of the draft standards by section
OECI team
3. Feedback from participants
4. Issues, conclusions and next steps
Simon Oberst

Cancer Outcomes Research Working Group Session

Feasibility of an OECI collaborative study on cancer outcomes

The rationale of the OECI WG on Outcomes is to try and launch outcome study involving OECI institutes and relative registries both clinical and population-based in their areas. 25 OECI Members (from 15 EU countries) replied to the 75 questionnaire circulated in 2017 to explore the interest and feasibility to carry out outcome studies. From this survey it emerged that breast (14 centres) and colorectal cancer (11 centres) were most frequently indicated as suitable for outcome studies, possibly focusing on clinical outcomes commonly available through health, hospital registries, or using the information included in the A&D questionnaire.

SESSION 1 Chair: Milena Sant

15.00-15.20 Cancer Outcomes studies and Population based cancer Registries: interest and feasibility among OECI Centres
Milena Sant

15.20-15.50 Outcome results from real-life treatment practice for colorectal cancer in Belgium and some European countries
Dominique de Valeriola

15.50-16.10 Integration of hospital based breast cancer data and population based data at the Greater Poland Cancer Centre and experiences in Poland with biobanks
Maciej Trojanowski

16.10-17.40 Panel of discussion on the feasibility to implement one / two pilot studies and how to finance them
Chair: Josep Borras
Discussants: Giovanni Apolone, Otto Visser, Tanja Marinko, Maja Ebert Moltara, Kaire Innos, Maria José Bento and other WCO representatives

17.20-17.40 A common research program of the OECI Institutes and research collaboration between European Oncology and Palliative Care Organisations
Stein Kaasa

17.40-18.00 Conclusions and next steps

AIMS
1. to define a short list of 2 / 3 easily clinical indicators for studies (initially) on breast and/or colorectal cancers
2. to formalise the availability from a group of OECI Members to start with a pilot
3. to agree on a "NEXT STEP TIMELINE"

The discussion will touch on the following issues:
1. Availability of clinical records in the participating centres
2. Availability of a database to be used for extraction purposes
3. Possibility of record linkage with external sources to obtain the patients’ life status and also with external sources to obtain information on treatments and hospitalisation from other centres in the country
4. Availability of disease phase (first diagnosis, recurrence / progression of the disease)
5. Availability of number of patients only partially treated in the center

SUPPORTIVE AND PALLIATIVE CARE WG
SUPPORTIVE AND PALLIATIVE CARE WG
Scientific Conference
Emerging technologies in therapies against cancer: what best to select for cancer Centres?

09.00-10.20  **Session 1**  
Limiting invasiveness of radiotherapy  
Chair: Guy Storme

09.20-09.40  Radiotheranostics  
Patrick Flamen

09.40-10.00  Image-guided and innovative radiotherapy  
Piotr Milecki

10.00-10.20  IORT in rectal cancer  
Olga Sousa

10.20-10.40  Coffee Break

10.40-12.00  **Session 2**  
Debating the future of hadrontherapy  
Chair: Roberto Orecchia

11.00-11.20  Is there a bonus for patients undergoing hadrontherapy so far?  
Guy Storme

11.20-11.40  9 years experience with protons and 20 years with carbon ions  
Klaus Herfarth

11.40-12.00  The Italian experience and the CNAO facility  
Roberto Orecchia

12.00-13.20  **Session 3**  
Minimally-invasive technologies: pros and cons  
Chair: Julian Malicki

12.20-12.40  Endoscopic approach of the solitary pulmonary nodule in 2018  
Dimitri Leduc

12.40-13.00  Image-guided treatment  
Theo Ruers

13.00-13.20  Head & Neck robot assisted surgery  
Wojciech Golusinski

13.20-14.20  Lunch

14.20-15.40  **Session 4**  
Health economic issues on emerging technologies  
Chair: Wim H. van Harten

14.40-15.00  How do health systems decide on investing in innovative technologies in cancer?  
Josep Borras

15.00-15.20  Cost effectiveness on scenarios of introducing image-guided surgery  
Valesca Retel

15.20-15.40  Cost effectiveness and decisions on Proton Beam Therapy  
Alejandro Mazal

15.40-16.00  General Discussion
Collaboration for Good Practices with Patients (CGPP)
Working Group Session

Expanding patient involvement in quality improvement

Quality improvement in cancer care and research is a major goal shared by both health care professionals and patients. Today, some innovative cancer centers are taking initiatives, involving patients, and leading the way forward to achieve this objective. In this session, different strategies of patient involvement and different examples of current collaborations between cancer centres and patient organisations will be presented, illustrating the variety of solutions and potential approaches that could be adopted across Europe.

16.00-16.20 Survey on patient involvement in OECI Centres
Patrick Miqueu

16.20-16.40 Collaboration with local and national Organisations in Finland: initiatives at the Tampere University Hospital Cancer Centre
Anne Kairenius and Emmi Tolvonen

16.40-17.00 Public and patient involvement in research at the Kings’ Health Partners Comprehensive Cancer Centre
Ambi Williams

17.00-17.30 Discussion and next steps
Dominique de Valeriola

17.30 End of the meeting

Accreditation & Designation Board Meeting

15.00-16.00 Accreditation & Designation Board Meeting
Restricted to A&D Board Members

OECI re-accreditation proposals: how to focus on quality improvements whilst not overburdening Centres
Chair: Simon Oberst

Discussion by OECI Member Organisations

Theme:
As quality of cancer care in European Centres generally improves, a whole industry of accreditations and certifications is growing, which places an increasing burden on Centres which are developing at different rates. The OECI is committed to quality improvement, and believes that the A&D Programme is a flagship for European Accreditation systems, which needs to remain robust and set high standards. But re-accreditation processes every 5 years need to be nimble and focus on areas of need for improvement, rather than re-auditing well-established systems. This meeting is being called to make draft proposals to member Organisations and gain feedback.
General Assembly

08.00 Registration

08.15 General Assembly Constitution, welcome and approval of the Agenda
Dominique de Valeriola

08.30 Session 1: Administrative and financial matters
Chair: Dominique de Valeriola

Point 1: Approval of June 2017 General Assembly's Minutes
(vote requested - decision to be taken at simple majority of the OECI Full Members present or represented)
Dominique de Valeriola

Point 2: Approval of the Financial Statement 2017 and discharge to the Board
(vote requested - decision to be taken at simple majority of the OECI Full Members present or represented)
José Maria Laranja Pontes

Point 3: Proposal of modification of OECI yearly membership fees
(vote requested - decision to be taken by unanimity of the OECI Full Members present or represented)
Dominique de Valeriola

Point 4: Proposal of modification of the Article 6.2 of the OECI Statute - Associate members
(vote requested - decision to be taken by simple majority of the OECI Full Members present or represented)
José Maria Laranja Pontes

Point 5: OECI 2018 and 2019 Provisional Budgets
(vote requested - decision to be taken by simple majority of the OECI Full Members present or represented)
José Maria Laranja Pontes

Point 6: OECI Board composition
Dominique de Valeriola

6.1 Board composition for the coming years
(vote requested - decision to be taken at simple majority of the OECI Full Members present or represented)

6.2 Hand-over of the 2014-2018 Presidency, and transfer of powers to the 2018-2021 Presidency
(vote not requested)

Point 7: Working Groups and Co-opted Board Members update
(vote not requested)
Thierry Philip

Point 8: New applications for membership
vote requested for full membership - decision to be taken by unanimity of the OECI Full Members present or represented;
for associate membership - decision to be taken by simple majority of the OECI Full Members present or represented
Claudio Lombardo

Point 9: Oncology Days for the coming years
Thierry Philip

10.45 Coffee break

11.00 Session 2: The OECI Strategy and Working Group activities
Chair: Thierry Philip

Accreditation & Designation
Simon Oberst

Collaboration for Good Practices with Patients
Dominique de Valeriola

Biobanks and Molecular Pathobiology
Giorgio Stanta

Health economics
Wim H. van Harten

Cancer Outcomes Research
Milena Sant

Supportive and Palliative Care
Tiina Hannele Saarto

Closure of the 2018 General Assembly
Thierry Philip

13.00 Lunch
Chairpersons and invited speakers

**OECI2018 ONCOLOGY DAYS**

**Chairpersons and invited speakers**

Giovanni **Apolone**  
Fondazione IRCCS- Istituto Nazionale dei Tumori di Milano, Italy

Matti **Aapro**  
European CanCer Organisation (ECCO), Brussels, Belgium

Maria José **Bento**  
North Regional Cancer Registry, IPO Porto, Portugal

Jean-Yves **Blay**  
Institut Léon Bérard, Lyon, France

Serena **Bonin**  
Università degli Studi di Trieste, Italy

Josep **Borràs**  
Institut Català d’Oncologia, Barcelona, Spain

Nicola **Crossetto**  
Karolinska Institute, Stockholm, Sweden

Dominique **de Valeriola**  
Institut Jules Bordet and National Cancer Registry, Brussels, Belgium

Manfred **Dietel**  
Charité Comprehensive Cancer Centre, Berlin, Germany

Patrick **Flamen**  
Institut Jules Bordet, Brussels, Belgium

Wojciech **Golusinski**  
Wielkopolskie Centrum Onkologii, Poznań, Poland

Klaus **Herfarth**  
University of Heidelberg, Germany

Kaire **Innos**  
National Institute of Health Development, Tallin, Estonia

Anne **Kairenius**  
Tampere University Hospital, Finland

Stein **Kaasa**  
European Society for Medical Oncology (ESMO), Brussels, Belgium

Claudio **Lombardo**  
Organisation of the European Cancer Institutes, Brussels, Belgium

José Maria **Laranja Pontes**  
Instituto Português de Oncologia do Porto Francisco Gentil, Portugal

Dimitri **Leduc**  
Hôpital Erasme, Brussels, Belgium

Julian **Malicki**  
Wielkopolskie Centrum Onkologii, Poznań, Poland

Tanja **Marinko**  
Institute of Oncology Liubljana, Slovenia

Andrzej **Marszalek**  
Wielkopolskie Centrum Onkologii, Poznań, Poland

Alejandro **Mazal**  
Institut Curie, Paris, France

Enzo **Medico**  
Istituto di Candiolo FPO-IRCCS, Turin, Italy

Piotr **Milecki**  
Wielkopolskie Centrum Onkologii, Poznań, Poland

Patrick **Miqueu**  
Institut Jules Bordet, Brussels, Belgium

Maja Ebert **Moltar**  
Institute of Oncology Ljubljana, Slovenia

Simon **Oberst**  
Cambridge Cancer Centre (CRUK), Cambridge, United Kingdom

**OECI2018 ONCOLOGY DAYS**

**Chairpersons and invited speakers**

Uwe **Oelmueller**  
QIAGEN, Hilden, Germany

Roberto **Orecchia**  
Fondazione CNAO, Pavia / Istituto Europeo di Oncologia, Milan, Italy

Thierry **Philip**  
Institut Curie, Paris, France

Valesca **Retel**  
Netherlands Cancer Institute, Amsterdam, The Netherlands

Theo **Ruers**  
Technical University Twente, Amsterdam, The Netherlands

Tina Hannele **Saarto**  
HYKS Syöpäkeskus Helsinki University, Finland

Milena **Sant**  
Fondazione IRCCS-Istituto Nazionale Tumori, Milan, Italy

Olga **Sousa**  
Instituto Português de Oncologia do Porto Francisco Gentil, Portugal

Giorgio **Stanta**  
Università degli Studi di Trieste, Italy

Guy **Storme**  
UZVUB / Organisation of the European Cancer Institutes, Brussels, Belgium

Carina **Strell**  
Karolinska Institute and University Hospital, Stockholm, Sweden

Emmi **Toivonen**  
Association of Cancer Patients, Finland

Maciej **Trojanowski**  
Wielkopolskie Centrum Onkologii, Poznan, Poland

Daniela **Valenti**  
European Association of Palliative Care (EAPC), Brussels, Belgium

Dalibor **Valík**  
Masaryk Memorial Cancer Institute, Brno, Czech Republic

Wim H. **van Harten**  
Rijnstate Hospital, Arnhem, The Netherlands

Otto **Visser**  
National Cancer Registry, IKNL, Utrecht, The Netherlands

Ambi **Williams**  
King’s Health Partners Integrated Cancer Centre, London, United Kingdom

Vesna **Zadnik**  
Institute of Oncology Ljubljana, NCCP, Ljubljana, Slovenia

Branko **Zakotnik**  
Institute of Oncology Ljubljana, NCCP, Ljubljana, Slovenia

**DEVELOPING THE FUTURE IN COMPREHENSIVE CANCER CARE**
OECI2018 Oncology Days

Organisation of European Cancer Institutes Official OECI Journal

BAR 2019 GENERAL ASSEMBLY, SCIENTIFIC CONFERENCES AND RELATED EVENTS

Bari, Italy
June 19th-21st 2019

Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari - Italy
THE OECI 2018 SCIENTIFIC COMMITTEE

 Presidents
 Dominique de Valeriola and Julian Malicki

 Members

THE OECI 2018 LOCAL ORGANISING COMMITTEE

 President
 Julian Malicki

THE OECI 2018 ONCOLOGY DAYS SECRETARIATS

 BRUSSELS: Maria Cummins, Lutgarde D’Hauwers
 GENOA: Giorgia Pesce, Patrizia Sommella, Roxana Plesoianu
 POZNAŃ: Sylwia Ciesinska, Kamila Przybylska

OECI 2018 ONCOLOGY DAYS COORDINATING OFFICE

 Claudio Lombardo - OECI Director
 Phone +32 2 512 01 46
 E-mail: oeci@oeci.eu
 www.oeci.eu

With the kind support of

Under the auspices of

TO REGISTER:
http://www.oeci.eu/Assembly.aspx